Citius Oncology, Inc.

NASDAQ:CTOR

Drug Manufacturers - General

Healthcare
$0.56 +4.23%

+$0.03 today

Market cap
$51.83M
Beta
3.42
P/E (TTM)
-1.6
EPS (TTM)
-$0.42
52W Low $0.49High $6.19

Volume 0.15M

Average 0.12M

CTOR Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Citius Oncology, Inc.NASDAQ: CTOR

Net Margin · Q2 FY2026 · quarter ended Mar 2026

Net margin at -1596.0%

Net margin was -1596.0% in Q2 FY2026. On a trailing-twelve-month basis it was -757.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-1596.0%-1455.7 pp QoQ
Last fiscal yearSep 2025
—— YoY
LTMMar 2026
-757.6%— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

No Net Margin data reported for this period type.

Net Margin vs competitors

How CTOR compares with its peers on the latest reported figures

  • CTOR's LTM Mar 2026 net margin of -757.6% is the 4th highest of the 7 companies compared; the peer median is -641.2%.
CTOR Competitors Peer median
Net Margin for CTOR and competitors
Company Period LTM level YoY 3-year change
LNSRLENSAR, Inc.LTM Mar 202650.9% +150.1 pp-2.3 pp
SPROSpero Therapeutics, Inc.LTM Mar 202627.8% +184.3 pp+109.9 pp
OWLTOwlet, Inc.LTM Mar 2026-43.0% -27.9 pp+77.1 pp
CTORCitius Oncology, Inc.LTM Mar 2026-757.6% ——
SCLXScilex Holding CompanyLTM Mar 2026-1239.4% -1092.4 pp-1124.4 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-2056.8% -737.9 pp-1758.5 pp
MCRBSeres Therapeutics, Inc.LTM Mar 2026-4088.8% ——
FBRXForte Biosciences, Inc.FY2025— ——
VORVor Biopharma Inc.FY2025— ——
ACTUActuate Therapeutics IncFY2025— ——
Peer median (excluding CTOR) -641.2%-27.9 pp-2.3 pp

Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development6.86M4.24M4.93M6.42M
Selling, General & Admin2.86M7.88M15.65M17.1M
Operating Expenses9.71M12.12M20.57M23.52M
Depreciation & Amortization9.71M000
EBITDA0(12.12M)(20.57M)(23.49M)
EBITDA Margin————
Operating Income(9.71M)(12.12M)(20.57M)(23.52M)
Operating Margin————
Interest Income00036.37K
Interest Expense000218.03K
Other Income / Expenses000(181.66K)
Income Before Tax(9.71M)(12.12M)(20.57M)(23.7M)
Pre-Tax Margin————
Income Tax Expense1.15M576K576K1.06M
Net Income(10.87M)(12.7M)(21.15M)(24.76M)
Net Margin————
EPS (Basic)(0.08)(0.19)(0.30)(0.34)
EPS (Diluted)(0.08)(0.19)(0.30)(0.34)
Weighted Avg Shares90.16M89.48M71.55M73.27M
Weighted Avg Shares (Diluted)90.16M89.48M71.55M73.27M

Citius Oncology, Inc.

NASDAQ:CTOR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.